Payment overview · 2025
General Payments
$121.83
1 reported records · 1 companies
Healthcare provider profile · identity verified
Chetna A Dave, MD
Allopathic & Osteopathic Physicians|Internal Medicine · STRATFORD, NJ · NPI 1831179134
Verified facts
What the public records show
CMS Open Payments records show Chetna A Dave, MD received $121.83 in general payments during 2025 across 1 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $121.83 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $121.83 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $121.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 630 | 77 |
| Divalproex Sodium | Divalproex Sodium | 436 | 46 |
| Amlodipine Besylate | Amlodipine Besylate | 394 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 387 | 53 |
| Risperidone | Risperidone | 374 | 37 |
| Gabapentin | Gabapentin | 358 | 43 |
| Levothyroxine Sodium | Levothyroxine Sodium | 357 | 39 |
| Mirtazapine | Mirtazapine | 286 | 38 |
| Olanzapine | Olanzapine | 276 | 25 |
| Trazodone Hcl | Trazodone Hcl | 266 | 35 |
| Buspirone Hcl | Buspirone Hcl | 242 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 236 | 24 |
| Furosemide | Furosemide | 232 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 216 | 26 |
| Potassium Chloride | Potassium Chloride | 213 | 23 |
| Eliquis | Apixaban | 212 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 199 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 152 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 147 | 20 |
| Sertraline Hcl | Sertraline Hcl | 145 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 144 | 31 |
| Metformin Hcl | Metformin Hcl | 139 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 138 | 15 |
| Donepezil Hcl | Donepezil Hcl | 135 | 20 |
| Lisinopril | Lisinopril | 133 | 18 |
| Clonazepam | Clonazepam | 124 | 16 |
| Clozapine | Clozapine | 118 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 114 | suppressed |
| Lactulose | Lactulose | 104 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 104 | 26 |
| Warfarin Sodium | Warfarin Sodium | 103 | suppressed |
| Losartan Potassium | Losartan Potassium | 100 | 14 |
| Levetiracetam | Levetiracetam | 98 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 96 | suppressed |
| Lorazepam | Lorazepam | 91 | 20 |
| Benztropine Mesylate | Benztropine Mesylate | 87 | 12 |
| Tramadol Hcl | Tramadol Hcl | 85 | 14 |
| Carvedilol | Carvedilol | 81 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 79 | suppressed |
| Memantine Hcl | Memantine Hcl | 79 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 77 | 12 |
| Aripiprazole | Aripiprazole | 76 | suppressed |
| Latanoprost | Latanoprost | 74 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 66 | 28 |
| Sucralfate | Sucralfate | 65 | suppressed |
| Famotidine | Famotidine | 63 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 57 | suppressed |
| Flucytosine | Flucytosine | 57 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 57 | suppressed |
| Ketoconazole | Ketoconazole | 55 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 54 | 12 |
| Paliperidone Er | Paliperidone | 54 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 51 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 51 | suppressed |
| Cephalexin | Cephalexin | 50 | 22 |
| Insulin Lispro | Insulin Lispro | 50 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 50 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 49 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 48 | suppressed |
| Finasteride | Finasteride | 46 | suppressed |
| Permethrin | Permethrin | 46 | 34 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 45 | 41 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 42 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 41 | suppressed |
| Haloperidol | Haloperidol | 41 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 41 | suppressed |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Allopurinol | Allopurinol | 39 | suppressed |
| Simvastatin | Simvastatin | 39 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 17 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 37 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | suppressed |
| Rexulti | Brexpiprazole | 36 | suppressed |
| Topiramate | Topiramate | 36 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 36 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 35 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 34 | suppressed |
| Prednisone | Prednisone | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Olanzapine Odt | Olanzapine | 33 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 32 | suppressed |
| Lamotrigine | Lamotrigine | 32 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 32 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Nystatin | Nystatin | 31 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 29 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 27 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 27 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 26 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 26 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 26 | suppressed |
| Omeprazole | Omeprazole | 26 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 24 | suppressed |
| Lumigan | Bimatoprost | 24 | suppressed |
| Tivicay | Dolutegravir Sodium | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Loperamide | Loperamide Hcl | 23 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 21 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Lidocaine | Lidocaine | 21 | suppressed |
| Calcitriol | Calcitriol | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 19 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 19 | suppressed |
| Lacosamide | Lacosamide | 19 | suppressed |
| Procrit | Epoetin Alfa | 19 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 19 | suppressed |
| Budesonide | Budesonide | 18 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 18 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 18 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 17 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 12 |
| Spironolactone | Spironolactone | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Mresvia | Rsv Vaccine, Pref, Mrna/Pf | 16 | 16 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 16 | suppressed |
| Posaconazole | Posaconazole | 16 | suppressed |
| Prezcobix | Darunavir/Cobicistat | 16 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 16 | suppressed |
| Alprazolam | Alprazolam | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 14 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 14 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Erythromycin | Erythromycin Base | 13 | suppressed |
| Pegasys | Peginterferon Alfa-2a | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 12 |
| Primidone | Primidone | 12 | suppressed |
| Risperidone Odt | Risperidone | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 12 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 11 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 11 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 11 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $121.83 · 1 records | Otsuka America Pharmaceutical, Inc. | REXULTI | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Otsuka America Pharmaceutical, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error